K18 – the Key to Unlocking Informed Decisions in MASH Drug Trials

Join us for an enlightening webinar presented by Jessica Tuohy, a distinguished partner and colleague from the US, focusing on the significance of K18 as a biomarker in the development of treatments for MASH (Metabolic Associated Steatohepatitis). This webinar is essential for drug developers, doctors, researchers, and key opinion leaders in the field of metabolic liver diseases, offering deep insights and key research findings.

Event Details:

  • Date: Tuesday, April 23
  • Time: [1pm EDT, 7pm CET]

Webinar Overview: This session will cover several critical areas:

  • – An Introduction to the Growing Epidemic of MASLD (Metabolic Associated Steatotic Liver Disease)
  • – Challenges in Developing Therapies for the Treatment of MASH
  • – An Overview of K18 and Its Role in MASH Pathogenesis
  • – A Review of Data That Support the Value of K18 as a Biomarker for Assessing the Efficacy of Drug Candidates in MASH Clinical Trials

Who Should Attend:

  • – Drug developers in the field of MASLD and MASH.
  • – Physicians and healthcare professionals specializing in hepatology, gastroenterology, and related fields.
  • – Medical researchers focusing on liver disease and drug development.
  • – Key opinion leaders in metabolic liver diseases.

Registration: Please register here to secure your spot in this informative webinar. Registration is required to access this online event.

Additional Information: If you are unable to attend the live event, a recording will be made available to all registered participants, ensuring you can access this webinar at your convenience.

We look forward to welcoming you to what promises to be an informative and transformative session.

For more information, please contact us at marketing@vlvbio.com.

Don’t miss out on the chance to advance your knowledge in MASH treatment and diagnostics. Reserve your spot today!